Michael Chambers

About

Michael Chambers is the Co-Founder at Agathos Biologics.Michael’s vision and leadership of Aldevron has resulted in several milestones including the 2004 acquisition of Genovac Antibody Technology of Freiburg, Germany; the 2009 expansion of protein production in Madison, Wisconsin; private equity transactions by TA Associates in 2017 and EQT in 2020; and the purchase of Aldevron by Danaher for $9.6 billion in 2021. Michael is committed to ethical pharmaceutical development and his leadership will enable Agathos to create new paradigms in biotechnology to achieve these goals. Michael received Bachelor of Science degrees in biotechnology, chemistry, and microbiology from North Dakota State University.

Investment Focus

Stages

seed

Location

Fargo, US